Location History:
- Tokyo-To, JP (2004 - 2007)
- Machida, JP (2010 - 2012)
- Tokyo, JP (2005 - 2014)
Company Filing History:
6 out of 272 
4 out of 3,199 
1 out of 92 
Years Active: 2004-2014
Title: Kazuhiro Masuda: Innovator in Antibody Development
Introduction
Kazuhiro Masuda is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of 11 patents to his name, Masuda's work has the potential to impact various therapeutic areas.
Latest Patents
One of his latest patents is an anti-CD4 antibody that binds to CD4 with high affinity and exhibits high effector activity, such as antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cellular cytotoxicity (CDC). This invention is crucial for diseases related to CD4-expressing cells. It provides a monoclonal antibody or an antibody fragment that binds to the CD4 extracellular region, along with a hybridoma that produces the antibody, a DNA encoding the antibody, and a process for producing the antibody or its fragments. Another notable patent involves a monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor (HB-EGF). This invention addresses the demand for medicaments treating diseases related to HB-EGF escalation.
Career Highlights
Throughout his career, Kazuhiro Masuda has worked with notable companies such as Kyowa Hakko Kirin Co., Limited and Dai Nippon Printing Co., Ltd. His experience in these organizations has contributed to his expertise in antibody development and biotechnology.
Collaborations
Masuda has collaborated with esteemed colleagues, including Kazuyasu Nakamura and Eisuke Mekada. These partnerships have likely enhanced his research and innovation efforts in the field.
Conclusion
Kazuhiro Masuda's contributions to antibody development and biotechnology are noteworthy. His innovative patents and collaborations reflect his commitment to advancing medical science. His work continues to pave the way for new therapeutic solutions.